EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
hVIVO PLC (AIM:HVO) EUR3.2m Venn contract with global pharma client
€3.2m contract for Venn Life Sciences with global pharmaceutical client
hVIVO PLC (AIM:HVO) £5.2m RSV contract and Notice of Trading update
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
4d Pharma PLC (AIM:DDDD) Update on Administration and Suspension of Trading
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Cathal Friel, chairman and co-founder of Poolbeg Pharma. What keeps him going is ‘the fun and enjoyment of creating companies’
Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market.
hVIVO PLC (AIM:HVO) Imutex Phase I data published
Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
Smarttech247 Group (AIM:S247) Admission to AIM and First Day of Dealings
Smarttech247, a multi-award-winning provider of AI enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, announces that its Ordinary Shares will today be admitted
Deepverge PLC (AIM:DVRG) Accelerated Restructuring
DeepVerge (AIM: DVRG) announces an organisational restructure of its environmental and life science divisions to meet the growth in demand and maximise the opportunities that lie ahead.
4d Pharma PLC (AIM:DDDD) Blautix Phase II Clinical Trial Results Published
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
hVIVO PLC (AIM:HVO) £13.6m RSV human challenge study contract with biopharma client
Study cohort sizes increase as clients recognise the benefits of human challenge
Deepverge PLC (AIM:DVRG) Board and Management changes
DeepVerge (AIM: DVRG), announces that further to the announcements of 25 October 2022 and 3 November 2022, Gerard Brandon, Executive Director with responsibility for the Modern Water Division, has resigned